Antisense Therapy of Cancer
A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Human Genomics and Genetic Diseases".
Deadline for manuscript submissions: 20 February 2025 | Viewed by 73
Special Issue Editor
Special Issue Information
Dear Colleagues,
Antisense and small interfering RNA (siRNA) therapies represents one of the most promising strategies in molecular oncology. These therapeutic approaches focus on the specific inhibition of gene expression responsible for tumor progression. Antisense DNA sequences and siRNAs work by pairing with their target messenger RNA (mRNA), blocking its translation into oncogenic proteins, thereby aiming to reduce cellular proliferation and induce apoptosis in tumor cells.
The potential of antisense oligonucleotides and siRNAs for genetic modulation has shown significant promise in preclinical and clinical studies. However, to maximize the efficacy and safety of these therapies, it is crucial that ongoing advancements are made in several areas. These include chemical modifications of oligonucleotides and siRNAs to improve their stability and activity, the development of efficient delivery systems for these therapeutic agents, and the optimization of their performance in vivo.
In this context, we invite researchers and scientists to contribute works exploring the latest advances in antisense therapy for cancer. We seek studies that delve into the evolution of chemical modifications that enhance the activity and stability of oligonucleotides, as well as new strategies for the efficient delivery of these therapeutic agents to tumor cells. Collaboration in these areas is essential to overcome current barriers and successfully advance antisense therapy from the lab to the clinic.
Dr. Jaime E. Villegas
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antisense and cell proliferation
- apoptosis
- solid tumors
- delivery and stability
- clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
